1. Scrip
  2. >>Focus On Asia

Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount

Another In Works From Hetero

 
• By Vibha Ravi

Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy

pink-breast-cancer-ribbon
Zydus's Ujvira Will Reduce Cost Of Breast Cancer Therapy • Source: Shutterstock

In a significant milestone, Zydus Cadila has launched in India the world’s first biosimilar to Roche Holding AG's Kadcyla (trastuzumab emtansine), used to treat early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

At INR32,495 ($446) for a 100mg vial, Zydus Cadila’s brand Ujvira will be available at an 80% discount to Kadcyla’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.